Stroke Prophylaxis With Apixaban in Chronic Kidney Disease Stage 5 Patients With Atrial Fibrillation
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 1400 participants.
Also called NCT05679024
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 1,400 participants
- Sponsor
- Registry
-
NCT05679024
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Finland, Iceland, Norway, Sweden
- Registry status
- Recruiting
Technical summary
Registry record NCT05679024. Randomized; no masking; primary purpose treatment. Start 2023-02-17 (actual); primary completion 2027-12-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Stroke Prophylaxis With Apixaban in Chronic Kidney Disease Stage 5 Patients With Atrial Fibrillation
- Acronym
- SACK
- Condition
- Chronic Kidney Diseases
- Condition
- Atrial Fibrillation
- Condition
- Stroke
- Condition
- Intracerebral Hemorrhage
- Condition
- Major Bleed
- Condition
- Cardiovascular Complication
- Condition
- Death
- Condition
- Kidney Transplant; Complications
- Condition
- Thromboses, Venous
- Intervention (Drug)
- Apixaban 2.5 milligram Oral Tablet
- Lead sponsor
- Region Stockholm
Record details
- Record id
cardio:ct-nct05679024- Content hash
f639a9b2a56a5ff025f50fc936402d5122ea771961ed059153ef0dbfccec5daa